Atossa Genetics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
632.60
526.00
1.80
-
-
44.20
Cost of Goods Sold (COGS) incl. D&A
968.40
905.10
405.00
303.50
129.00
44.20
Gross Income
335.80
379.20
403.30
303.50
129.00
44.20
SG&A Expense
10,290.50
11,910.60
12,355.30
6,946.10
7,058.50
11,390
EBIT
10,626.40
12,289.80
12,758.60
7,249.60
7,187.50
11,434.20
Unusual Expense
158.30
2,352.60
-
1,044.00
742.50
-
Non Operating Income/Expense
-
-
0.40
163.20
0.20
29.30
Interest Expense
0.40
15.80
-
-
192.80
-
Pretax Income
10,784.70
14,657.90
12,758.20
6,368.90
8,122.60
11,404.90
Consolidated Net Income
10,784.70
14,657.90
12,758.20
6,368.90
8,122.60
11,404.90
Net Income
10,784.70
14,657.90
12,758.20
6,368.90
8,122.60
11,404.90
Net Income After Extraordinaries
10,784.70
14,657.90
9,756.10
6,368.90
8,122.60
11,404.90
Net Income Available to Common
10,784.70
14,657.90
15,089.40
6,368.90
10,690.70
22,884.20
EPS (Basic)
126.00
109.80
99.00
25.92
10.92
5.50
Basic Shares Outstanding
86.00
133.50
157.90
245.60
974.80
4,157.70
EPS (Diluted)
125.37
109.76
99.79
25.93
10.97
5.50
Diluted Shares Outstanding
86.00
133.50
157.90
245.60
974.80
4,157.70
EBITDA
10,153.40
11,725.30
12,486.00
6,946.10
7,058.50
11,390
Non-Operating Interest Income
0.30
0.30
-
-
-
-
Preferred Dividends
-
-
-
-
2,568.10
11,479.30

About Atossa Genetics

View Profile
Address
107 Spring Street
Seattle Washington 98104
United States
Employees -
Website http://www.atossagenetics.com
Updated 07/08/2019
Atossa Genetics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65.